Viradux Research, Ltd. Has Expanded the Number of International Shipping Destinations Worldwide and Has Enhanced Its Anti-Herpetic Cream and Lipbalm
Viradux Research, Ltd. announced today that it has expanded the number of international shipping destinations worldwide. Additionally, Viradux has just released to market an improved formulation of its leading anti-herpetic cream Viradux-AU.
Los Angeles, CA, February 13, 2015 --(PR.com)-- Bob Hastings, director of marketing at Viradux Research, Ltd. announced, “It has been our intention to ship worldwide by the end of 2014. Although a few countries remain walled off due to international sanctions, Viradux products are now available throughout the free world.”
On the topic of continuous improvements to the Viradux product formulations Mr. Hastings added, "Preliminary observations are suggesting up to 39% improvement in viral responsiveness when compared to the first generation Viradux-AU." This was reportedly achieved by expanding the effectiveness of several key protein inhibitors found in compounds already known to have anti-viral properties. “The combined modality of these well-known elements with our existing delivery system had raised the overall effectiveness. Our original expectation was a fairly modest increase. We are now seeing over 84% of users describing their experience as (completely satisfied with outcome after 10 months). These preliminary results exceeded our expectations and give us some interesting avenues to pursue.”
The reformulated compound began shipping in August of 2014 and is now widely available to people, and their partners, whose lives have been impacted by genital herpes. “Our ultimate goal,” continued Mr. Hastings “is a product that is able to eradicate all the various types and sub-types of HSV2 infection with 100% effectiveness. I’m also pleased to announce that there are no expected pricing increases and the 2 oz. container will remain priced below $30 USD for the near term.”
Viradux Research, Ltd is a provider of anti-herpetic treatment solutions targeted at the rapid resolution of symptoms related to HSV1 and HSV2 infections. A multi-faceted solution to HSV2 (typically genital) infections is provided in the form of an anti-herpetic topical treatment, marketed globally under the trade-name Viradux-AU™. This solution has also been shown to reduce symptoms, speed healing and prevent future outbreaks in people with moderate to severe HSV2 infections. In 2013, Viradux Research, Ltd released to market Viradux-ColdSore™ as the only effective anti-herpetic HSV1 treatment currently available based on type-III epidermal transportation compounds. Viraudx-ColdSore™ lip balm has been shown to speed healing of existing herpetic lesions and prevent the reoccurrence of future outbreaks associated with moderate-to-severe HSV-1 infection.
Further information regarding research results, product information, and viral epidemiology can be found at the company's websites: Viradux Home Page and Viradux-ColdSore Home Page
On the topic of continuous improvements to the Viradux product formulations Mr. Hastings added, "Preliminary observations are suggesting up to 39% improvement in viral responsiveness when compared to the first generation Viradux-AU." This was reportedly achieved by expanding the effectiveness of several key protein inhibitors found in compounds already known to have anti-viral properties. “The combined modality of these well-known elements with our existing delivery system had raised the overall effectiveness. Our original expectation was a fairly modest increase. We are now seeing over 84% of users describing their experience as (completely satisfied with outcome after 10 months). These preliminary results exceeded our expectations and give us some interesting avenues to pursue.”
The reformulated compound began shipping in August of 2014 and is now widely available to people, and their partners, whose lives have been impacted by genital herpes. “Our ultimate goal,” continued Mr. Hastings “is a product that is able to eradicate all the various types and sub-types of HSV2 infection with 100% effectiveness. I’m also pleased to announce that there are no expected pricing increases and the 2 oz. container will remain priced below $30 USD for the near term.”
Viradux Research, Ltd is a provider of anti-herpetic treatment solutions targeted at the rapid resolution of symptoms related to HSV1 and HSV2 infections. A multi-faceted solution to HSV2 (typically genital) infections is provided in the form of an anti-herpetic topical treatment, marketed globally under the trade-name Viradux-AU™. This solution has also been shown to reduce symptoms, speed healing and prevent future outbreaks in people with moderate to severe HSV2 infections. In 2013, Viradux Research, Ltd released to market Viradux-ColdSore™ as the only effective anti-herpetic HSV1 treatment currently available based on type-III epidermal transportation compounds. Viraudx-ColdSore™ lip balm has been shown to speed healing of existing herpetic lesions and prevent the reoccurrence of future outbreaks associated with moderate-to-severe HSV-1 infection.
Further information regarding research results, product information, and viral epidemiology can be found at the company's websites: Viradux Home Page and Viradux-ColdSore Home Page
Contact
viradux
Bob Hastings
1-800-800-3434
www.viradux.com
Bob Hastings
1-800-800-3434
www.viradux.com
Contact
Categories